Skip to main content
Search Open Menu Close Menu

FoundationOne®Heme

Jump To

What is FoundationOne Heme?

FoundationOne Heme

FoundationOne Heme is a comprehensive genomic profiling (CGP) test combining DNA and RNA sequencing for patients with hematologic malignancies, sarcomas or solid tumors where RNA sequencing is desired. FoundationOne Heme detects known, novel, and complex fusion events as well as other common genomic alterations (substitutions, indels, and CNVs). This laboratory developed test (LDT) can be used by physicians to identify potential targeted therapy options, detect alterations in prognostic genes, and sub-classify sarcoma diagnoses. 

Order a Test

Test Features

>400 DNA-sequenced genes and >250 RNA-sequenced genes

Combines DNA and RNA sequencing to detect all four main classes of genomic alterations, including sensitive identification of translocations and fusions

Valuable insights to help guide treatment strategies

Expansive gene panel provides broad coverage across guideline-recommended genes in leukemias and MDS.¹⁻³

Multiple sample types accepted

FoundationOne Heme is validated for FFPE tissue, peripheral whole blood, bone marrow aspirate, and extracted nucleic acid

FAQ and Resources

FoundationOne Heme Resources

FAQs

View all Provider FAQs

Resources

View Additional Resources

Real-life Results

Real-life Results

Learn more about the clinical utility of FoundationOne Heme in a number of cancer types.

  • SAMPLE REPORT

    FoundationOne Heme Acute Myeloid Leukemia (AML) Sample Report

    View a FoundationOne Heme AML sample report. This report shows results with an IDH2 and TET2 alteration detected.

    DOWNLOAD SAMPLE REPORT

  • BLOG POST

    Can Rapid Precision Medicine Help Older Adults With AML?

    The findings from the Beat AML Master trial offer new insights that, we believe, can help change clinical practice because they validate a framework for rapid precision medicine that improves outcome. Because blood cancers are so complex, they require a sophisticated strategy to understand each patient’s unique cancer as well as the treatments that have the best chance at improving survival.

    READ FULL BLOG POST

  • SAMPLE REPORT

    FoundationOne Heme Acute B-Lymphocytic Leukemia (B-ALL) Sample Report

    View a FoundationOne Heme B-ALL sample report. This report shows results with an ABL1 alteration detected.

    DOWNLOAD SAMPLE REPORT

  • PUBLICATION

    Genomic Landscape of Adult and Pediatric BCR‐ABL1 ‐Like B‐Lymphoblastic Leukemia Using Parallel DNA and RNA Sequencing

    Comprehensive genomic profiling performed on 450 patients with extensive fusion profiling revealed a wide range of genomic alterations which were consistent with a classification of BCR‐ABL1‐like B‐ALL in 29% of cases.

    VIEW PUBLICATION

  • SAMPLE REPORT

    FoundationOne Heme Sarcoma Sample Report

    View a FoundationOne Heme Sarcoma sample report. This report shows results that include elevated TMB, high-MSI status, and an NTRK1 rearrangement detected.

    DOWNLOAD SAMPLE REPORT

  • BLOG POST

    CTOS 2019: Navigating the sarcoma maze with CGP

    With more than 80 subtypes, sarcomas can be susceptible to misdiagnosis, and there are very limited treatment guidelines beyond standard chemotherapy.4 This is where comprehensive genomic profiling (CGP) can help remove the guess work by identifying alterations in the genes driving the cancer that might be prognostic or inform targeted therapies.

    READ FULL BLOG POST

We Have Even More to Offer

Learn more about our other tests: FoundationOne®CDx and FoundationOne®Liquid CDx. You can also explore our decision support, report integration, and clinical research and trial matching services.

Need More Details?

Our client services team is here to help, Monday through Friday 8AM – 8PM EST. 

Contact Us

Additional Notes

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

1Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.3.2021. © National Comprehensive Cancer Network, Inc. 2021.  All rights reserved. Accessed April 30, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.

2Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.1.2021. © National Comprehensive Cancer Network, Inc. 2021.  All rights reserved. Accessed April 30, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.

3Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myelodysplastic Syndromes V.3.2021. © National Comprehensive Cancer Network, Inc. 2021.  All rights reserved. Accessed April 30, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.

4Casali, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Annals of Oncology. 2018;29(Supp 4):iv51-iv67. doi:10.1093/annonc/mdy096.

FoundationOne Heme was developed and its performance characteristics determined by Foundation Medicine.  It has not been cleared or approved by the U.S. Food and Drug Administration. For more information on our laboratory developed test (LDT) please see the Technical Specifications at www.foundationmedicine.com.